Natural products marketed to “boost immunity” are advancing faster than clinical science can define which immune responses are genuinely beneficial. A study of microparticulate Physalis angulata fruit extract and propolis shows biological signals in cells and animals but also reveals non-linear dose responses and a substantial translational gap between changes in leukocytes, splenic white pulp, and CD206 expression and meaningful protection in humans. This perspective proposes a shift from immune boosting to context-dependent immunomodulation. Development should proceed through three evidence layers: product identity and consistency, mechanism and therapeutic window, and clinically relevant benefit. Under this framework, an increased biomarker is not automatically interpreted as stronger immunity, and a multicomponent formulation should not be described as synergistic until the contribution and safety of its components are established.
Copyrights © 2026